MX2014007031A - Terapia para hemorragia subaracnoidea e isquemia. - Google Patents
Terapia para hemorragia subaracnoidea e isquemia.Info
- Publication number
- MX2014007031A MX2014007031A MX2014007031A MX2014007031A MX2014007031A MX 2014007031 A MX2014007031 A MX 2014007031A MX 2014007031 A MX2014007031 A MX 2014007031A MX 2014007031 A MX2014007031 A MX 2014007031A MX 2014007031 A MX2014007031 A MX 2014007031A
- Authority
- MX
- Mexico
- Prior art keywords
- aneurysm
- subjects
- subarachnoid hemorrhage
- endovascular
- psd
- Prior art date
Links
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 title abstract 3
- 208000028867 ischemia Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 206010002329 Aneurysm Diseases 0.000 abstract 3
- 229940123119 PSD-95 Inhibitor Drugs 0.000 abstract 2
- 238000001356 surgical procedure Methods 0.000 abstract 2
- 206010048380 Aneurysm ruptured Diseases 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 abstract 1
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La solicitud proporciona datos a partir de un ensayo clínico de un inhibidor de PSD-95 en sujetos que experimentan reparación endovascular de un aneurisma en o de otro modo que afecta el SNC. Los sujetos se estratificaron en función de si el aneurisma se rompió antes de realizar la cirugía endovascular. La ruptura se asoció con mayor mortalidad o debilidad incrementada si el sujeto sobrevivió. El ensayo proporcionó evidencia de beneficio significativo en sujetos con y sin ruptura del aneurisma antes de que se realizara la cirugía endovascular. De manera sorprendente los sujetos que se beneficiaron más del tratamiento según se juzgó tanto por la patología como por el resultado neurocognitivo fueron aquellos en los cuales el aneurisma se rompió causando una hemorragia subaracnoidea. Estos datos constituyen la evidencia de que un inhibidor de PSD-95 es benéfico no solo en isquemia y choque hemorrágico sino en formas de hemorragia en o que afectan el SNC, particularmente hemorragia subaracnoidea.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570264P | 2011-12-13 | 2011-12-13 | |
| CA2762338A CA2762338C (en) | 2011-12-13 | 2011-12-15 | Therapy for subarachnoid hemorrhage and ischemia |
| US201261617001P | 2012-03-28 | 2012-03-28 | |
| PCT/IB2012/057259 WO2013088382A1 (en) | 2011-12-13 | 2012-12-13 | Therapy for subarachnoid hemorrhage and ischemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014007031A true MX2014007031A (es) | 2015-02-20 |
| MX364562B MX364562B (es) | 2019-04-30 |
Family
ID=51228598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014007031A MX364562B (es) | 2011-12-13 | 2012-12-13 | Terapia para hemorragia subaracnoidea e isquemia. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2800575B1 (es) |
| JP (3) | JP6279483B2 (es) |
| KR (2) | KR102114490B1 (es) |
| CN (1) | CN104053448B (es) |
| AU (1) | AU2012354072B2 (es) |
| DK (1) | DK2800575T3 (es) |
| ES (1) | ES2731266T3 (es) |
| IL (1) | IL233103B (es) |
| MX (1) | MX364562B (es) |
| SG (2) | SG11201403239UA (es) |
| WO (1) | WO2013088382A1 (es) |
| ZA (1) | ZA201404636B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1010718A2 (pt) | 2009-06-10 | 2016-03-15 | Nono Inc | sistemas modelo e regimes de tratamento para tratar doença neurológica. |
| KR102022116B1 (ko) | 2011-06-24 | 2019-09-18 | 노노 인코포레이티드 | 허혈에 대한 psd-95 억제제와의 조합 요법 |
| US9241970B2 (en) | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
| EP3074032B1 (en) * | 2013-12-01 | 2018-12-26 | University of Copenhagen | Fatty acid derivatives of dimeric inhibitors of psd-95 |
| KR102605540B1 (ko) | 2014-05-28 | 2023-11-22 | 노노 인코포레이티드 | Tat-nr2b9c의 클로라이드 염 |
| KR20180135493A (ko) * | 2016-04-27 | 2018-12-20 | 바이오셀즈(베이징) 바이오테크 코., 엘티디. | 흥분성 신경독성 관련 손상의 치료 방법 |
| CN107312071B (zh) * | 2016-04-27 | 2018-11-06 | 拜西欧斯（北京）生物技术有限公司 | 兴奋性神经毒性相关损伤的治疗方法 |
| CN109985047B (zh) * | 2017-12-29 | 2021-07-27 | 广州市赛普特医药科技股份有限公司 | 5α-雄甾-3β,5,6β-三醇在制备治疗出血性脑卒中药物中的应用 |
| CN109009111A (zh) * | 2018-07-16 | 2018-12-18 | 重庆大学 | 低场核磁共振脑出血动态监护仪控制系统 |
| CN113284126B (zh) * | 2021-06-10 | 2022-06-24 | 安徽省立医院(中国科学技术大学附属第一医院) | 人工神经网络图像分析预测脑积水分流手术疗效的方法 |
| CN113735938B (zh) * | 2021-07-30 | 2024-11-08 | 英纳氏(珠海)药业有限公司 | 一种神经保护多肽化合物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| EP1884521A1 (en) * | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| EP2120987B1 (en) * | 2007-03-02 | 2014-01-15 | NoNO Inc. | Treating stroke and other diseases without inhibiting n-type calcium channels |
| BRPI1010718A2 (pt) * | 2009-06-10 | 2016-03-15 | Nono Inc | sistemas modelo e regimes de tratamento para tratar doença neurológica. |
-
2012
- 2012-12-13 KR KR1020147019192A patent/KR102114490B1/ko not_active Expired - Fee Related
- 2012-12-13 JP JP2014546717A patent/JP6279483B2/ja not_active Expired - Fee Related
- 2012-12-13 KR KR1020207014227A patent/KR20200057802A/ko not_active Ceased
- 2012-12-13 MX MX2014007031A patent/MX364562B/es active IP Right Grant
- 2012-12-13 AU AU2012354072A patent/AU2012354072B2/en not_active Ceased
- 2012-12-13 CN CN201280061924.1A patent/CN104053448B/zh not_active Expired - Fee Related
- 2012-12-13 ES ES12857611T patent/ES2731266T3/es active Active
- 2012-12-13 SG SG11201403239UA patent/SG11201403239UA/en unknown
- 2012-12-13 WO PCT/IB2012/057259 patent/WO2013088382A1/en not_active Ceased
- 2012-12-13 EP EP12857611.3A patent/EP2800575B1/en active Active
- 2012-12-13 SG SG10201604676WA patent/SG10201604676WA/en unknown
- 2012-12-13 DK DK12857611.3T patent/DK2800575T3/da active
-
2014
- 2014-06-12 IL IL233103A patent/IL233103B/en active IP Right Grant
- 2014-06-24 ZA ZA2014/04636A patent/ZA201404636B/en unknown
-
2017
- 2017-11-10 JP JP2017217549A patent/JP6741642B2/ja not_active Expired - Fee Related
-
2020
- 2020-05-15 JP JP2020085748A patent/JP2020128419A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013088382A1 (en) | 2013-06-20 |
| JP2018052962A (ja) | 2018-04-05 |
| CN104053448B (zh) | 2017-04-05 |
| KR20200057802A (ko) | 2020-05-26 |
| DK2800575T3 (da) | 2019-07-01 |
| EP2800575A4 (en) | 2015-09-23 |
| ES2731266T3 (es) | 2019-11-14 |
| JP6279483B2 (ja) | 2018-02-14 |
| ZA201404636B (en) | 2015-10-28 |
| IL233103B (en) | 2021-03-25 |
| JP2015501834A (ja) | 2015-01-19 |
| IL233103A0 (en) | 2014-07-31 |
| SG10201604676WA (en) | 2016-07-28 |
| JP6741642B2 (ja) | 2020-08-19 |
| KR102114490B1 (ko) | 2020-05-25 |
| MX364562B (es) | 2019-04-30 |
| AU2012354072A1 (en) | 2014-07-03 |
| EP2800575B1 (en) | 2019-05-22 |
| SG11201403239UA (en) | 2014-09-26 |
| EP2800575A1 (en) | 2014-11-12 |
| JP2020128419A (ja) | 2020-08-27 |
| CN104053448A (zh) | 2014-09-17 |
| KR20140108266A (ko) | 2014-09-05 |
| AU2012354072B2 (en) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX364562B (es) | Terapia para hemorragia subaracnoidea e isquemia. | |
| MX2022002786A (es) | Inhibidores del reciclaje de acidos biliares para el tratamiento de colangitis esclerosante primaria y enfermedad inflamatoria intestinal. | |
| BR112015028482A2 (pt) | implante cirúrgico que compreende uma camada que tem aberturas | |
| MX2008013454A (es) | Metodos y equipos para la prediccion de riesgo en partos prematuros. | |
| BR112015022218A2 (pt) | composições e sua utilização para tratar complicações da hemorragia subaracnóidea aneurismática | |
| SG10201510118VA (en) | Use of refrigerants comprising e-1,3,3,3-tetrafluoropropene and at least one tetrafluoroethane for cooling | |
| MY185054A (en) | Rolled collagen carrier | |
| BR112015001521A2 (pt) | previsão de resposta ao tratamento para inibidor jak/stat | |
| MY148893A (en) | Combination of an hdac inhibitor and an antimetabolite | |
| MY165571A (en) | Treatment of excessive menstrual bleeding associated with uterine fibroids | |
| WO2006026557A3 (en) | Methods and kits for predicting risk for peterm labor | |
| RU2012149809A (ru) | Способ прогнозирования прогрессирования первичной открытоугольной глаукомы | |
| GB201112455D0 (en) | Ceramide C16-Cer and CerS6 in the treatment and diagnosis of multiple sclerosis (MS) | |
| Macdonald | Whether subarachnoid hemorrhage depends on the weather? | |
| UA62588U (ru) | Способ хирургического лечения артериовенозных мальформаций головного мозга | |
| WO2015092444A3 (en) | Biomarkers | |
| Macdonald | Dissecting the complexities of aneurysm hemodynamics | |
| 郭建明 | Surgical treatment of visceral artery aneurysms | |
| EP2392338A4 (en) | PROPHYLACTIC OR THERAPEUTIC FOR DISEASES RELATED TO ABNORMAL BONE MATERIAL CHANGE | |
| PH12015501458A1 (en) | A use of the mixture of a salt and sugar in the manufacture of a medicament employed for treating lax vagina syndrome or colpoxerosis disease in a mammal | |
| UA84482C2 (ru) | Способ неотложного хирургического лечения пациентов с идиопатической тромбоцитопенической пурпурой, осложненной внутрибрюшным кровотечением | |
| FR2963832B1 (fr) | Procede de quantification de l'effet potentialisateur du fibrinogene sur la generation de thrombine et ses applications | |
| EP2722050A4 (en) | USE OF OLIVE OIL FOR THE PREVENTION AND TREATMENT OF DISEASES THROUGH ISCHEMIC PROCESSES | |
| WO2014052803A3 (en) | Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension | |
| LV14231A (lv) | Olnīcu hiperstimulācijas sindroma rašanās novēršanas līdzeklis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |